EP0579683A1 - Material - Google Patents

Material

Info

Publication number
EP0579683A1
EP0579683A1 EP92908385A EP92908385A EP0579683A1 EP 0579683 A1 EP0579683 A1 EP 0579683A1 EP 92908385 A EP92908385 A EP 92908385A EP 92908385 A EP92908385 A EP 92908385A EP 0579683 A1 EP0579683 A1 EP 0579683A1
Authority
EP
European Patent Office
Prior art keywords
material according
diol
glycol
acid
polyurethane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP92908385A
Other languages
German (de)
French (fr)
Inventor
Peter Neuenschwander
Falah Redha
Ulrich W. Suter
Georg Uhlschmid
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SUTER, ULRICH W.
UHLSCHMID, GEORG K.
Original Assignee
JECK Juliane
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by JECK Juliane filed Critical JECK Juliane
Publication of EP0579683A1 publication Critical patent/EP0579683A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0442—Polymeric X-ray contrast-enhancing agent comprising a halogenated group

Definitions

  • plastics in industry, agriculture, medicine or other fields of application are often associated with the question of the ability to be localized and the material being tested during its use.
  • the implanted or applied plastics not only have to be securely localizable, but also have the property that they can be removed from the human or animal body after a certain time. The removal usually requires further (surgical) intervention.
  • Plastics which are easy to locate are known, but are chemically stable and can therefore only be removed from the human body by a surgical procedure.
  • plastics are known that dissolve after a certain time when they have fulfilled their task. However, the latter plastics cannot be easily located.
  • the object of the invention is to create a material which, on the one hand, can be localized with high accuracy and, on the other hand, can also be degraded in the human or animal body.
  • radiopaque polyurethanes are particularly well suited for the tasks described above.
  • X-ray-tight polyurethanes are particularly suitable for the production of temporary or permanent polyurethane applications in connection with X-ray identification.
  • the polyurethane In the solid aggregate state, devices, structures, films, foils, tubes, hoses, screws, rods or other three-dimensional elements are seared from the polyurethanes to make compact or hollow structures, and the polyurethane is also used for coatings on structures, insulation, seals and suitable as a drug carrier.
  • the polyurethane can used to fill empty or filled biological or technical cavities for therapeutic and / or diagnostic, medical or technical purposes.
  • the polyurethane can be used to coat structures for the additional purpose of X-ray identification.
  • the polyurethane can also be used in the form of sprays, dispersions or as dispersants. Workpieces can be coated with this polyurethane, and topical application is not excluded. Thereby solidification takes place with external energy.
  • the plastic to be used has some special properties, such as. E.g .: a) Biocompatibility
  • b) be soluble in non-toxic or only slightly toxic solvents, such as alcohol, dimethyl sulfoxide, DMI or mixtures thereof
  • c) be insoluble in an aqueous environment (water, blood, etc.)
  • polyurethanes are suitable in which one of their two basic components, here the diol component, is wholly or partly by the glyceryl monoester (1) of a triiodobenzoic acid derivative (2, 3, 4, 5) or a pyridone-4 derivative, for example iopydol (6) , is replaced.
  • polyester diols based on II-V are produced by reversing the corresponding higher molecular weight polyesters with ethylene glycol, diaethylene glycol and triaethylene glycol with simultaneous cleavage to macrodiols with average molecular weights between M n 500 and 10,000.
  • TMDI 2,2,4-trimethylhexamethylene diisocyanate
  • the condensation of the components takes place in solution in a mixture of dioxane / dimethylformamide with a mixing ratio between 1: 1 to 20: 1 at temperatures between 40 ° and 100 ° with or without a catalyst.
  • the polymers are isolated by precipitation in water.
  • the cleaning is done by repeatedly dissolving the polymer and precipitating in water.
  • polymer made from the components described above can be illustrated by the following formula:

Abstract

La présente invention se rapporte à un matériau en polyuréthanne comportant des substances de contraste à liaison covalente pour la radiographie, le polyuréthanne étant biocompatible, stable, ou bien, dans un milieu adéquat, également biodégradable, ainsi que contrastant en radiographie.The present invention relates to a polyurethane material comprising covalently bonded contrast substances for radiography, the polyurethane being biocompatible, stable, or else, in a suitable medium, also biodegradable, as well as contrasting in radiography.

Description

We r k s t o f f  We r k s t o f f
Werkstoff aus Polyurethan mit covalent gebundenem Röntgenkontrastmittel. Material made of polyurethane with covalently bound X-ray contrast medium.
Die Verwendung von Kunststoffen in der Industrie, Landwirtschaft, Medizin oder anderen Anwendungsgebieten ist oft mit der Frage der Lokalis ierbarkeit und Prüfung des Werkstoffes während seines Einsatzes verbunden. In der Medizin kommt hinzu, daß die implantierten oder applizierten Kunststoffe nicht nur sicher lokalisierbar sein, sondern auch die Eigenschaft besitzen müssen, daß sie nach einer bestimmten Zeit aus dem menschlichen oder tierischen Körper entfernbar sind. Die Entfernung verlangt in der Regel einen weiteren (chirurgischen) Eingriff. Es sind zwar einfach lokalisierbare Kunststoffe bekannt, die jedoch chemisch beständig sind und somit nur durch einen chirurgischen Eingriff aus dem menschlichen Körper entfernt werden können. Andererseits sind Kunststoffe bekannt, die sich nach einer bestimmten Zeit auflösen, wenn sie ihre Aufgabe erfüllt haben. Die letztgenannten Kunststoffe sind allerdings nicht ohne weiteres lokalisierbar. The use of plastics in industry, agriculture, medicine or other fields of application is often associated with the question of the ability to be localized and the material being tested during its use. In medicine there is also the fact that the implanted or applied plastics not only have to be securely localizable, but also have the property that they can be removed from the human or animal body after a certain time. The removal usually requires further (surgical) intervention. Plastics which are easy to locate are known, but are chemically stable and can therefore only be removed from the human body by a surgical procedure. On the other hand, plastics are known that dissolve after a certain time when they have fulfilled their task. However, the latter plastics cannot be easily located.
In dem Derwent-Abstract 87-348546/49 der WO 8707-155 ist ein röntgenopakes Polyurethan offenbart, das jedoch nicht biologisch abbaubar ist. Sollte es diese Eigenschaft besitzen, so würden hoch toxische Halogenderivate der Isophtalsäure entstehen, durch die das Polymer nicht biokombatibel wäre. In J. Polym. Sei, Polym. Symp. 66, S. 259 - 268 (1979) oder J. Polym. Sei., Polym. Symp. 66. S. 239 - 257 (1979) sowie Houben-Weyl, Methoden der organischen Chemie, Band E 20, Makromol. Stoffe, S. 1719-1721 (1987) sind biokompatible und/oder biodegradierbare Polyurethane offenbart, die jedoch nicht röntgenkontrastierend sind. Derwent abstract 87-348546 / 49 of WO 8707-155 discloses an X-ray-opaque polyurethane which, however, is not biodegradable. If it had this property, highly toxic halogen derivatives of isophthalic acid would result, which would make the polymer not biocompatible. In J. Polym. Be Polym. Symp. 66, Pp. 259-268 (1979) or J. Polym. Be., Polym. Symp. 66. pp. 239-257 (1979) and Houben-Weyl, Methods of Organic Chemistry, Volume E 20, Makromol. Fabrics, pp. 1719-1721 (1987) disclose biocompatible and / or biodegradable polyurethanes, which, however, are not X-ray contrasting.
Ausgehend von dem obigen Stand der Technik liegt der Erfindung die Aufgabe zugrunde, einen Werkstoff zu schaffen, der zum einen mit hoher Genauigkeit lokalisierbar und zum anderen im menschlichen oder tierischen Körper auch abbaubar ist. On the basis of the above prior art, the object of the invention is to create a material which, on the one hand, can be localized with high accuracy and, on the other hand, can also be degraded in the human or animal body.
Die gestellte Aufgabe wird erfindungsgemäß durch Merkmale des Anspruches 1 gelöst. The object is achieved according to the invention by the features of claim 1.
Diese röntgenopaquen Polyurethane eignen sich besonders gut für die oben beschriebenen Aufgaben. These radiopaque polyurethanes are particularly well suited for the tasks described above.
Weitere zweckmäßige und vorteilhafte Ausgestaltungen der Erfindung gehen aus den Unteransprüchen hervor. Further expedient and advantageous refinements of the invention emerge from the subclaims.
Röntgendichte Polyurethane sind besonders für die Herstellung von temporärer oder permanenter Polyurethananwendung in Verbindung mit Röntgenidentifizierung geeignet. Im festen Aggregat zustand werden aus den Polyurethanen Geräte, Strukturen, Filme, Folien, Röhren, Schläuche, Schrauben, Stäbe oder andere d r e i d i me n s i on a l e kompakte oder hohle Strukturen gesenaffen, und dabei ist das Polyurethan auch für Überzüge von Strukturen, Isolationen, Dichtungen und als Drugcarrier geeignet. Im flüssigen Aggregatzustand kann das Polyurethan zur Füllung von leeren oder gefüllten biologischen oder technischen Hohlräumen zu therapeutischen und/oder diagnostischen, medizinischen oder technischen Zwecken verwendet werden. Ferner kann das Polyurethan zur Umhüllung von Strukturen zum zusätzlichen Zwecke der Röntgenidentifizierung angewandt werden. Anwendbar ist das Polyurethan auch in Form von Sprays, Dispersion oder als Dispersionsmittel. Mit diesem Polyurethan können Werkstücke beschichtet werden, eine topische Anwendung ist auch nicht ausgeschlossen. Dabei erfolgt eine Verfestigung mit externer Energieeinwirkung. X-ray-tight polyurethanes are particularly suitable for the production of temporary or permanent polyurethane applications in connection with X-ray identification. In the solid aggregate state, devices, structures, films, foils, tubes, hoses, screws, rods or other three-dimensional elements are seared from the polyurethanes to make compact or hollow structures, and the polyurethane is also used for coatings on structures, insulation, seals and suitable as a drug carrier. In the liquid state, the polyurethane can used to fill empty or filled biological or technical cavities for therapeutic and / or diagnostic, medical or technical purposes. Furthermore, the polyurethane can be used to coat structures for the additional purpose of X-ray identification. The polyurethane can also be used in the form of sprays, dispersions or as dispersants. Workpieces can be coated with this polyurethane, and topical application is not excluded. Thereby solidification takes place with external energy.
Beispiel: Die Blockierung des exokrinen Gangsystems der Bauchspeicheldrüse mittels Injektion des gelösten Kunststoffes über einen Katheter ist ein chirurgischer Eingriff, der bei der Transplantation dieses Organs notwendig sein kann. Example: Blocking the exocrine duct system of the pancreas by injecting the dissolved plastic through a catheter is a surgical procedure that may be necessary when transplanting this organ.
Der dabei anzuwendene Kunststoff hat aus medizinischer Sicht einige besondere Eigenschaften aufzuweisen, wie z. B.: a) Biokompatibilitat From a medical point of view, the plastic to be used has some special properties, such as. E.g .: a) Biocompatibility
b) lösbar sein in nicht oder nur wenig toxischen Lösungsmitteln, wie Alkohol, Dimenthylsulfoxyd, DMI oder deren Gemischen  b) be soluble in non-toxic or only slightly toxic solvents, such as alcohol, dimethyl sulfoxide, DMI or mixtures thereof
c) unlösbar sein in wässrigem Milieu (Wasser, Blut etc.)  c) be insoluble in an aqueous environment (water, blood, etc.)
d) festes, elastisches oder viskoelastisches Verhalten nach Fällung aufweisen  d) exhibit firm, elastic or viscoelastic behavior after precipitation
e) biologisch abbaubar zu sein  e) to be biodegradable
f) muß in hinreichendem und variierbarem Ausmaß röntgenabsorbierend sein. Für diese Zwecke eignen sich Polyurethane, bei denen einer ihrer beiden Grundkomponenten, hier die Diolkomponente, ganz oder teilweise durch den Glyceri nmonoester (1) eines Trijodbenzoesäurederivates (2, 3, 4, 5) oder eines Pyridon-4 Derivates, z.B.Jopydol (6), ersetzt ist. f) must be X-ray absorbing to a sufficient and variable extent. For this purpose, polyurethanes are suitable in which one of their two basic components, here the diol component, is wholly or partly by the glyceryl monoester (1) of a triiodobenzoic acid derivative (2, 3, 4, 5) or a pyridone-4 derivative, for example iopydol (6) , is replaced.
Als cokondensierbare Diol komponenten finden folgende Diole Anwendung : The following diols are used as co-condensable diol components:
a ) zweiwertige Alkohole vom Typ n = 2-12 a) dihydric alcohols of the type n = 2-12
b) Polyätherdiole vom Typ b) Type polyether diols
m = 2 - 6 n.p = 0 - 20  m = 2 - 6 n.p = 0 - 20
c) Polyätherdiole auf der Basis von c) polyether diols based on
I) Adipinsäure/Aethylenglykol-co-Propylenglykol Adipinsäure/Aethylenglykol I) adipic acid / ethylene glycol-co-propylene glycol adipic acid / ethylene glycol
Adipinsäure/Propylenglykol  Adipic acid / propylene glycol
II) Polyglykoldiol und Poly-glykol-co-lactid-diol II) Polyglycol diol and polyglycol-co-lactide diol
IV) Poly-3-hydroxybuttersäurediol und Poly-3- Hydroxybuttersäure-co-3-HydroxyvaleriansäurediolIV) Poly-3-hydroxybutyric acid diol and poly-3-hydroxybutyric acid-co-3-hydroxyvaleric acid diol
V) Poly-3-Hydroxy-valeriansäurediol V) Poly-3-hydroxy-valeric acid diol
VI) Polycaprolactondiol  VI) polycaprolactone diol
VII) Depolymerisierte Cellulose  VII) Depolymerized cellulose
VIII) Depolymerisiertes Celluloseacetat VIII) Depolymerized cellulose acetate
Die Polyesterdiole auf der Basis II-V werden hergestellt durch Umsteuerung an entsprechenden höhermolekularen Polyestern mit Aethylenglykol, Diaethylenglykol und Triaethylenglykol bei gleichzeitiger Spaltung zu Makrodiolen mit mittleren Molekulargewichten zwischen Mn 500 und 10000. The polyester diols based on II-V are produced by reversing the corresponding higher molecular weight polyesters with ethylene glycol, diaethylene glycol and triaethylene glycol with simultaneous cleavage to macrodiols with average molecular weights between M n 500 and 10,000.
Als Diisocyanate können folgende Verbindungen eingesetzt werden: The following compounds can be used as diisocyanates:
1) 5-Isocyanato-1-(isocyanatomethyl)-1,3,3- (IPDI) trimethylcyclohexan (Isophorondiisocyanat) 1) 5-isocyanato-1- (isocyanatomethyl) -1,3,3- (IPDI) trimethylcyclohexane (isophorone diisocyanate)
2) 1,3-Bis(1-isocyanato-1-methyl)-benzol (TMXDI) 2) 1,3-bis (1-isocyanato-1-methyl) benzene (TMXDI)
3) Hexamethylendiisocyanat (HDI) 3) hexamethylene diisocyanate (HDI)
4) 2,2,4-Trimethyl-hexamethylendiisocyanat (TMDI) 4) 2,2,4-trimethylhexamethylene diisocyanate (TMDI)
Die Kondensation der Komponenten erfolgt in Lösung in einem Gemisch Dioxan/Dimethylformami d mit einem Mischungsverhältnis zwischen 1:1 bis 20:1 bei Temperaturen zwischen 40° und 100° mit oder ohne Katalysator. Die Isolierung der Polymere erfolgt durch Ausfällung in Wasser. Die Reinigung erfolgt durch wiederholtes Lösen des Polymers und Fällen in Wasser. The condensation of the components takes place in solution in a mixture of dioxane / dimethylformamide with a mixing ratio between 1: 1 to 20: 1 at temperatures between 40 ° and 100 ° with or without a catalyst. The polymers are isolated by precipitation in water. The cleaning is done by repeatedly dissolving the polymer and precipitating in water.
Als Beispiel kann das aus den oben beschriebenen Komponenten hergestellte Polymer durch folgende Formel veranschaulicht werden: As an example, the polymer made from the components described above can be illustrated by the following formula:

Claims

A n s p r ü c h e Expectations
1. Werkstoff aus Polyurethan mit covalent gebundenem1. Material made of polyurethane with covalently bound
Röntgenkontrastmittel, X-ray contrast media,
dadurch gekennzeichnet,  characterized,
daß das Polyurethan biokompatibel, beständig oder in entsprechendem Milieu auch biologisch abbaubar sowie röntgenkonstrastierend ist.  that the polyurethane is biocompatible, stable or, in an appropriate environment, also biodegradable and X-ray contrasting.
2. Werkstoff nach Anspruch 1, 2. Material according to claim 1,
dadurch gekennzeichnet,  characterized,
daß der Kunststoff lösbar ist in nicht oder nur wenig toxischen Lösungsmitteln, wie Alkohol, that the plastic is soluble in non-toxic or only slightly toxic solvents, such as alcohol,
Dimethy Isulfoxyd, 1,3, Dimethyl-2-imidazolidinonDimethy isulfoxide, 1,3, dimethyl-2-imidazolidinone
(DIM) oder deren Gemischen. (DIM) or their mixtures.
3. Werkstoff nach einem der Ansprüche 1 oder 2, 3. Material according to one of claims 1 or 2,
dadurch gekennzeichnet,  characterized,
daß der Kunststoff in wässrigem Milieu, z.B. Wasser, Blut etc., unlösbar ist.  that the plastic in an aqueous medium, e.g. Water, blood, etc., is insoluble.
4. Werkstoff nach einem der Ansprüche 1 bis 3, 4. Material according to one of claims 1 to 3,
dadurch gekennzeichnet,  characterized,
daß der Kunststoff feste, elastische oder viskoelastische Eigenschaften aufweist. that the plastic has firm, elastic or viscoelastic properties.
5. Werkstoff nach einem der Ansprüche 1 bis 4, 5. Material according to one of claims 1 to 4,
dadurch gekennzeichnet,  characterized,
daß bei den Polyurethanen eine ihrer beiden that one of their two in the polyurethane
Grundkomponenten, z.B. Diolkcmponente, ganz oder teilweise durch den Glycerinmonoester (1) einesBasic components, e.g. Diolkcmponente, whole or in part by the Glycerinmonoester (1) one
Trijodbenzoesäurederivates (2, 3, 4, 5) oder einesTriiodobenzoic acid derivative (2, 3, 4, 5) or one
Pyridon-4-Derivates, z.B. Iopydol (6), ersetzt ist. Pyridon-4 derivative, for example Iopydol (6), is replaced.
H  H
6. Werkstoff nach einem der Ansprüche 1 bis 9, 6. Material according to one of claims 1 to 9,
dadurch gekennzeichnet,  characterized,
dass als cokondensierbare Diolkomponente folgende Diole angewendet werden: a) zweiwertige Alkohole vom Typ n = 2-12 that the following diols are used as the co-condensable diol component: a) dihydric alcohols of the type n = 2-12
b) Polyätherdiole vom Typ b) Type polyether diols
m = 2 - 6 n.p = 0 - 20 c) Polyesterdiole auf der Basis von  m = 2 - 6 n.p = 0 - 20 c) polyester diols based on
I) Adipinsäure/Aethylenglykol-co-Propylenglykol Adipinsäure/Aethylenglykol I) adipic acid / ethylene glycol-co-propylene glycol adipic acid / ethylene glycol
Adipinsäure/Propylenglykol  Adipic acid / propylene glycol
II) Polyglykoldiol und Poly-glykol-co-lactid-diol II) Polyglycol diol and polyglycol-co-lactide diol
IV) Poly-3-hydroxybuttersäurediol und Poly-3- Hydroxybuttersäure-co-3-Hydroxyvaleriansäurediol IV) Poly-3-hydroxybutyric acid diol and poly-3-hydroxybutyric acid-co-3-hydroxyvaleric acid diol
V) Poly-3-Hydroxy-valeriansäurediol  V) Poly-3-hydroxy-valeric acid diol
VI) Polycaprolactondiol  VI) polycaprolactone diol
VII) Depolymerisierte Cellulose  VII) Depolymerized cellulose
VIII) Depolymerisiertes Cellulosetriacetat VIII) Depolymerized cellulose triacetate
7. Werkstoff nach einem der Ansprüche 1 bis 6 7. Material according to one of claims 1 to 6
dadurch gekennzeichnet,  characterized,
dass die Polyesterdiole auf der Basis II-V durch Umsteuerung an entsprechenden höhermolekularen Polyestern mit  that the polyester diols based on II-V by reversing the corresponding higher molecular weight polyesters
Aethylenglykol, Diaethylenglykol und Triaethyleπglykol bei gleichzeitiger Spaltung zu Makrodiolen mit mittleren  Aethylene glycol, diaethylene glycol and triaethylene glycol with simultaneous cleavage to macrodiols with medium
Molekulargewichten zvischen Mn 500 und 10000 herstellbar sind. Molecular weights between M n 500 and 10,000 can be produced.
8 . Werkstoff nach einem der Ansprüche l bis 7, 8th . Material according to one of claims 1 to 7,
dadurch gekennzeichnet,  characterized,
dass als Diisocyanate folgender Verbindunge eingesetzt werden:  that the following compounds are used as diisocyanates:
1) 5-Isocyanato-1-(isccyanatomethyl)-1,3,3- trimethylcyclohexan (Isophorondiisocyanat) (IPDI)1) 5-isocyanato-1- (isccyanatomethyl) -1,3,3-trimethylcyclohexane (isophorone diisocyanate) (IPDI)
2) 1,3-Bis(1-isocγanato-1-methyl)-benzol (TMXDI)2) 1,3-bis (1-isocγanato-1-methyl) benzene (TMXDI)
3) Hexamethylendiisocynat (MDI) 3) hexamethylene diisocynate (MDI)
4) 2,2,4-Trimethyl-hexamethylendiisocyanat (TMDI) 4) 2,2,4-trimethylhexamethylene diisocyanate (TMDI)
9. Werkstoff nach einem der Ansprüche 1 bis 8 , 9. Material according to one of claims 1 to 8,
dadurch gekennzeichnet,  characterized,
dass die Kondensation der Komponenten in Lösung in einem  that the condensation of the components in solution in one
Gemisch Dioxan/Dimethylformamid mit einem Mischungsverhältnis zwischen 1:1 bis 20:1 bei Temperaturen zwischen 40°C und 100°C mit und ohne Katalysator erfolgt. Mixture of dioxane / dimethylformamide with a mixing ratio between 1: 1 to 20: 1 at temperatures between 40 ° C and 100 ° C with and without a catalyst.
10. Werkstoff nach einem der Ansprüche 1 bis 9, 10. Material according to one of claims 1 to 9,
dadurch gekennzeichnet,  characterized,
daß die Isolierung des Polymers durch Ausfällung in Wasser oder Alkoholen erfolgt.  that the polymer is isolated by precipitation in water or alcohols.
11. Werkstoff nach einem der Ansprüche 1 bis 9, 11. Material according to one of claims 1 to 9,
dadurch gekennzeichnet,  characterized,
daß die Reinigung durch wiederholtes Lösen des Polymers und Fällen in Wasser erfolgt..  cleaning is done by repeatedly dissolving the polymer and precipitating in water.
12. Werkstoff nach einem der Ansprüche 1 bis 11, 12. Material according to one of claims 1 to 11,
dadurch gekennzeichnet,  characterized,
daß die Isolierung des Polymers folgende Formel aufweist. that the isolation of the polymer has the following formula.
EP92908385A 1991-04-12 1992-04-10 Material Ceased EP0579683A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4111914A DE4111914A1 (en) 1991-04-12 1991-04-12 MATERIAL
DE4111914 1991-04-12

Publications (1)

Publication Number Publication Date
EP0579683A1 true EP0579683A1 (en) 1994-01-26

Family

ID=6429413

Family Applications (1)

Application Number Title Priority Date Filing Date
EP92908385A Ceased EP0579683A1 (en) 1991-04-12 1992-04-10 Material

Country Status (5)

Country Link
US (1) US5319059A (en)
EP (1) EP0579683A1 (en)
JP (1) JPH06506494A (en)
DE (1) DE4111914A1 (en)
WO (1) WO1992018167A1 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4419386C2 (en) 1994-05-30 1996-09-19 Ivoclar Ag X-ray opaque esters and amides of iodine-substituted benzoic acid and their use in the production of dental materials
DE69510460T2 (en) * 1994-09-22 2000-01-13 Guerbet Villepinte IODO COMPOUNDS, THEIR PRODUCTION AND USE AS CONTRAST AGENTS FOR X-RAY RADIOLOGY
DE69510527T2 (en) * 1994-09-22 2000-01-27 Guerbet Villepinte IODO DERIVATIVES THEIR PRODUCTION AND USE AS CONTRAST FOR X-RAY RADIOLOGY
US5711958A (en) * 1996-07-11 1998-01-27 Life Medical Sciences, Inc. Methods for reducing or eliminating post-surgical adhesion formation
US6696499B1 (en) * 1996-07-11 2004-02-24 Life Medical Sciences, Inc. Methods and compositions for reducing or eliminating post-surgical adhesion formation
US6426145B1 (en) 1999-05-20 2002-07-30 Scimed Life Systems, Inc. Radiopaque compositions for visualization of medical devices
US6599448B1 (en) * 2000-05-10 2003-07-29 Hydromer, Inc. Radio-opaque polymeric compositions
US8088158B2 (en) 2002-12-20 2012-01-03 Boston Scientific Scimed, Inc. Radiopaque ePTFE medical devices
WO2006026725A2 (en) 2004-08-31 2006-03-09 C.R. Bard, Inc. Self-sealing ptfe graft with kink resistance
JP2008522747A (en) * 2004-12-08 2008-07-03 クック・インコーポレイテッド Medical devices coated with contrast media
CA2610896C (en) 2005-06-17 2014-07-08 C.R. Bard, Inc. Vascular graft with kink resistance after clamping
JP5280852B2 (en) 2005-11-09 2013-09-04 シー・アール・バード・インコーポレーテッド Grafts and stent grafts with radiopaque markers
CA2626601A1 (en) * 2005-11-09 2007-05-18 C.R. Bard Inc. Grafts and stent grafts having a radiopaque beading
EP2079575B1 (en) * 2006-10-12 2021-06-02 C.R. Bard, Inc. Methods for making vascular grafts with multiple channels
GB0725070D0 (en) * 2007-12-21 2008-01-30 Iopharma Technologies Ab Product
JP5388455B2 (en) * 2008-01-28 2014-01-15 株式会社グツドマン Radiopaque biodegradable material and medical device using the same
JP2010024257A (en) * 2008-07-15 2010-02-04 Fujifilm Corp Biocompatible polymeric compound, biocompatible polymer, and polymer particle
US8808357B2 (en) * 2010-04-06 2014-08-19 Poly-Med, Inc. Radiopaque iodinated and iodide-containing crystalline absorbable aliphatic polymeric materials and applications thereof
DE102015220373A1 (en) 2014-10-23 2016-04-28 Voco Gmbh Hardenable dental material
WO2018065444A1 (en) 2016-10-04 2018-04-12 Cedar Advanced Technology Group Ltd. Laminary material for preventing post-surgical adhesions
US11407851B2 (en) 2016-12-02 2022-08-09 The Texas A&M University System Chemically modified shape memory polymer embolic foams with increased X-ray visualization
US11597792B2 (en) * 2017-10-30 2023-03-07 The Texas A&M University System Radiopaque thermoplastic polymer
EP4213903A1 (en) * 2020-09-16 2023-07-26 Said Farha System and method for integrated blood vessel embolization and localized drug delivery

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3733397A (en) * 1966-12-02 1973-05-15 Pharmacia Ab Method for the x-ray visualization of body cavities and a preparation for carrying out the method
US4406878A (en) * 1978-08-02 1983-09-27 Eastman Kodak Company Iodinated contrast agent for radiography
US4282876A (en) * 1979-05-18 1981-08-11 Flynn Vincent J Radiopaque polyurethane resin compositions
US4283447A (en) * 1979-05-18 1981-08-11 Flynn Vincent J Radiopaque polyurethane resin compositions
EP0073765A1 (en) * 1980-09-24 1983-03-16 National Research Development Corporation Radio-opaque material
US4581390A (en) * 1984-06-29 1986-04-08 Flynn Vincent J Catheters comprising radiopaque polyurethane-silicone network resin compositions
DE3661200D1 (en) * 1985-04-29 1988-12-22 Dow Chemical Co Radiopaque thermoset polymer
US4722344A (en) * 1986-05-23 1988-02-02 Critikon, Inc. Radiopaque polyurethanes and catheters formed therefrom
FR2610935B1 (en) * 1987-02-13 1989-09-01 Guerbet Sa IODINE POLYMERS, THEIR PREPARATION PROCESSES AND THEIR APPLICATIONS AS CONTRAST PRODUCTS
IE70756B1 (en) * 1990-04-11 1996-12-30 Becton Dickinson Co Radiopaque optically transparent medical tubing

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9218167A1 *

Also Published As

Publication number Publication date
JPH06506494A (en) 1994-07-21
US5319059A (en) 1994-06-07
DE4111914C2 (en) 1993-04-22
DE4111914A1 (en) 1992-10-15
WO1992018167A1 (en) 1992-10-29

Similar Documents

Publication Publication Date Title
DE4111914C2 (en)
DE3725728C2 (en)
Rusu et al. An insight into the structural diversity and clinical applicability of polyurethanes in biomedicine
EP0249603B1 (en) Anti-thrombogenic, uncalcifiable material and process for the production of medical articles
DE69934406T2 (en) POLYMERS FOR THE RELEASE OF NITROGEN MONOXIDE IN VIVO
EP0034375B1 (en) Silicon rubber mixture for therapeutic application and as a healing aid
DE60316291T2 (en) ESTER DERIVATIVES OF HYALURONIC ACID FOR THE PREPARATION OF HYDROGELIC MATERIALS BY PHOTO-PAINTING
DE69719328T3 (en) MEDICAL DEVICE
DE2844960A1 (en) USE OF MOLDABLE THERMOPLASTIC POLYMERIZES FOR FASTENING PROSTHESES TO BONES
CH683673A5 (en) Antithrombotic resin antithrombotic tubes, antithrombotic film and antithrombotic coating.
DE3434123A1 (en) HYALURONATE MODIFIED POLYMER ARTICLE
EP2108384A1 (en) Medical devices with an anti-bacterial polyurethane urea coating
EP2108386A1 (en) Medical devices with an anti-microbial polyurethaneurea coating
JPH11500330A (en) Antimicrobial medical device and method
EP2108388A1 (en) Aqueous silver containing non-ionic polyurethane dispersions
EP0550875A1 (en) Implantable polymeric device containing pharmaceutical agents and process for its production
Hannig et al. Impact of the springtail's cuticle nanotopography on bioadhesion and biofilm formation in vitro and in the oral cavity
EP2099370A2 (en) Tube for enteral nutrition
DE2833072A1 (en) PROCESS FOR MANUFACTURING BIOLOGICALLY COMPATIBLE MATERIALS AND THE OBJECTS OBTAINED BY THIS PROCESS
EP2240546B1 (en) Process for the production of instruments coated with iron oxide nanoparticles for invasive medicine
US10537659B2 (en) 3D printed polyvinyl alcohol medical devices and methods of activation
Musciacchio et al. Rifampicin-loaded electrospun polycaprolactone membranes: Characterization of stability, antibacterial effects and urotheliocytes proliferation
DE69733840T2 (en) IMPLANTABLE ARTIFICIAL TOOTH COAT WITH CHITOSAN
DE102009052725A1 (en) Use of polyoxyalkylenediamine-based polyguanidine derivatives for medical articles
DE102015014912B4 (en) Coating for a medical instrument, method for its coating and medical instrument coated with this method

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

17P Request for examination filed

Effective date: 19930825

17Q First examination report despatched

Effective date: 19960402

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: REDHA, FALAH

Owner name: NEUENSCHWANDER, PETER

Owner name: UHLSCHMID, GEORG K.

Owner name: SUTER, ULRICH W.

RIN1 Information on inventor provided before grant (corrected)

Inventor name: REDHA, FALAH

Inventor name: NEUENSCHWANDER, PETER

Inventor name: UHLSCHMID, GEORG K.

Inventor name: SUTER, ULRICH W.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20020225